Publication details

Kombinace obinutuzumab a venetoklax v léčbě chronické lymfocytární leukemie

Title in English The combination of obinutuzumab and venetoclax in the treatment of chronic lymphocytic leukemia
Authors

ARPÁŠ Tomáš PRCHLÍKOVÁ Adéla PANOVSKÁ Anna

Year of publication 2023
Type Article in Periodical
Magazine / Source Farmakoterapie
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.farmakoterapie.cz/c7497/kombinace-obinutuzumab-a-venetoklax-v-lecbe-chronicke-lymfocytarni-leukemie
Keywords chronic lymphocytic leukemia; venetoclax; obinutuzumab; first-line treatment
Attached files
Description Chronic lymphocytic leukemia (CLL) represents the most frequent leukemia in adults (with the incidence 6 per 100.000 in the Czech Republic). In the last years, thanks to the new targeted drugs development, we witness dramatic extension of treatment options in CLL. We can individualize the diagnostic process and treatment considering the age, comorbidities and patient’s preferences. Bcl-2 inhibitors represent one of these new targeted drugs in CLL treatment. Currently, the only one Bcl-2 inhibitor venetoclax is used in the routine clinical practice. Venetoclax treatment indications, efficacy and side effects when combined with anti-CD20 monoclonal antibody obinutuzumab will be discussed in the following text.

You are running an old browser version. We recommend updating your browser to its latest version.

More info